Millipore Sigma Vibrant Logo

567616 Sodium 4-Phenylbutyrate - CAS 1716-12-7 - Calbiochem

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
1716-12-7C₁₀H₁₁O₂Na

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
567616-100MG
Verfügbarkeit wird abgerufen...
Eingeschränkte Verfügbarkeit
Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      Kst.-Ampulle 100 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      Bitte erfragen
      Description
      OverviewA novel anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation. Increases fetal hemoglobin production in vitro and in vivo.
      Catalogue Number567616
      Brand Family Calbiochem®
      SynonymsSPB, PBNa, 4PBA, 4-Phenylbutyrate, Na, BDK Inhibitor I, BCKD Kinase Inhibitor I, Branched-Chain α-Ketoacid Dehydrogenase Kinase Inhibitor I
      References
      ReferencesTso, S.C., et al. 2013. Proc. Natl. Acad. Sci. USA 110, 9728.
      Ozcan, U., et al. 2006. Science 313, 1137.
      Carducci, M.A., et al. 2001. Clin. Cancer Res. 7, 3047.
      Rubenstein, R.C. and Zeitlin, P.L. 2000. Am.J. Physiol. Cell. Physiol. 278, C259.
      Lea, M.A., et al. 1999. Anticancer Res. 19, 1971.
      Miller, A.C., et al. 1997. Int. J. Radiat. Biol. 72, 211.
      Rubenstein, R.C., et al. 1997. J. Clin. Invest. 100, 2457.
      Pineau, T., et al. 1996. Biochem. Pharmacol. 52, 659.
      Collins, A.F., et al. 1995. Blood 85, 43.
      Lea, M.A., et al. 1995. Anticancer Res. 15, 879.
      Figg, W.D., et al. 1994. Anticancer Drugs 5, 336.
      Liu, L., et al. 1994. J. Invest. Dermatol. 103, 335.
      Product Information
      CAS number1716-12-7
      ATP CompetitiveN
      FormWhite to slightly yellow solid
      Hill FormulaC₁₀H₁₁O₂Na
      Chemical formulaC₁₀H₁₁O₂Na
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationSodium 4-Phenylbutyrate, CAS 1716-12-7, is a novel anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation.
      Biological Information
      Primary TargetAnti-neoplastic agent
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      567616-100MG 04055977266818

      Documentation

      Sodium 4-Phenylbutyrate - CAS 1716-12-7 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      Sodium 4-Phenylbutyrate - CAS 1716-12-7 - Calbiochem Analysenzertifikate

      TitelChargennummer
      567616

      Literatur

      Übersicht
      Tso, S.C., et al. 2013. Proc. Natl. Acad. Sci. USA 110, 9728.
      Ozcan, U., et al. 2006. Science 313, 1137.
      Carducci, M.A., et al. 2001. Clin. Cancer Res. 7, 3047.
      Rubenstein, R.C. and Zeitlin, P.L. 2000. Am.J. Physiol. Cell. Physiol. 278, C259.
      Lea, M.A., et al. 1999. Anticancer Res. 19, 1971.
      Miller, A.C., et al. 1997. Int. J. Radiat. Biol. 72, 211.
      Rubenstein, R.C., et al. 1997. J. Clin. Invest. 100, 2457.
      Pineau, T., et al. 1996. Biochem. Pharmacol. 52, 659.
      Collins, A.F., et al. 1995. Blood 85, 43.
      Lea, M.A., et al. 1995. Anticancer Res. 15, 879.
      Figg, W.D., et al. 1994. Anticancer Drugs 5, 336.
      Liu, L., et al. 1994. J. Invest. Dermatol. 103, 335.

      Broschüre

      Titel
      Caspases and other Apoptosis Related Tools Brochure
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision19-January-2024 JSW
      SynonymsSPB, PBNa, 4PBA, 4-Phenylbutyrate, Na, BDK Inhibitor I, BCKD Kinase Inhibitor I, Branched-Chain α-Ketoacid Dehydrogenase Kinase Inhibitor I
      DescriptionAn antineoplastic agent that demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. Acts as an inducer of tumor cytostasis and differentiation as well as of peroxisomal proliferation. A more effective inhibitor of histone deacetylase and inducer of histone acetylation than its structural analogs including 2- and 3-phenylbutyrate. Acts as a transcriptional regulator and improve the targeting of δF508-CFTR (cystic fibrosis transmembrane regulator) for ubiquitination and degradation by reducing the expression of HSC70 in epithelial cells. Also, reported to increase fetal hemoglobin production in vitro and in vivo.
      FormWhite to slightly yellow solid
      CAS number1716-12-7
      Chemical formulaC₁₀H₁₁O₂Na
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (10 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesTso, S.C., et al. 2013. Proc. Natl. Acad. Sci. USA 110, 9728.
      Ozcan, U., et al. 2006. Science 313, 1137.
      Carducci, M.A., et al. 2001. Clin. Cancer Res. 7, 3047.
      Rubenstein, R.C. and Zeitlin, P.L. 2000. Am.J. Physiol. Cell. Physiol. 278, C259.
      Lea, M.A., et al. 1999. Anticancer Res. 19, 1971.
      Miller, A.C., et al. 1997. Int. J. Radiat. Biol. 72, 211.
      Rubenstein, R.C., et al. 1997. J. Clin. Invest. 100, 2457.
      Pineau, T., et al. 1996. Biochem. Pharmacol. 52, 659.
      Collins, A.F., et al. 1995. Blood 85, 43.
      Lea, M.A., et al. 1995. Anticancer Res. 15, 879.
      Figg, W.D., et al. 1994. Anticancer Drugs 5, 336.
      Liu, L., et al. 1994. J. Invest. Dermatol. 103, 335.